Sangamo: First Look At June 2018 Results [Seeking Alpha]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Seeking Alpha
Summary Sangamo's hemophilia A gene therapy product candidate is showing positive preliminary clinical results to be announced at the ASH annual meeting in December. Sangamo's MPS II in vivo genome editing product candidate has a safety profile and early efficacy sufficient to amend the trial protocol to include younger patient enrollment soon. Other clinical programs are progressing. Operating results for the June 2018 quarter are summarized. In the first half of 2018 we made strong progress on important initiatives including our clinical development programs and execution of a significant collaboration with Kite-Gilead for the use of ZFNs for engineered cell therapies in oncology. —Sangamo CEO Sandy Macrae Sangamo ( SGMO ) reported 2Q18 earnings and provided program updates after the market closed on August 8, 2018. The clinical trial updates in particular improve the overall investment thesis. The hemophilia A product candidate appears to have a signi
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates [Yahoo! Finance]Yahoo! Finance
- BioMarin updated 2024 guidance sees EPS raise, but no change to revenue [Seeking Alpha]Seeking Alpha
- BioMarin Reports Record Financial Results for the First Quarter 2024 [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical Non-GAAP EPS of $0.71 beats by $0.11, revenue of $648.83M misses by $2.98M [Seeking Alpha]Seeking Alpha
BMRN
Earnings
- 4/24/24 - Beat
BMRN
Sec Filings
- 4/24/24 - Form 8-K
- 4/23/24 - Form 8-K
- 4/15/24 - Form 4
- BMRN's page on the SEC website